Module 9 2021

... what’s next (2)

Off-the shelf CART therapy ● T cells Genome editing via Β 2 M knock out

● Allogeneic CAR+T-NK ● In-vivo gene therapy

CART Solid tumors

Cost reduction ● Strimvelis: 600,000 EU / treatment ● Zalmoxis: 149,000 EU / treatment (4 treatments planned)

● Glybera: 1,000,000 $ / treatment ● Kymriah: ~ 475,000 $ / treatment ● Zongelsma: $425,000/year over 5 years

Novartis Pharma AG- Business use only- not for further distribution

13